Biological Active Reagents

Novel selective ionotropic glutamate receptor 5 (iGluR5) antagonist

Novel glucagon analog for diabetic hypoglycemia therapy

Novel PROTAC targeting drug-resistant BCR-ABL

Proteolysis targeting chimeras (PROTAC), acting as a degrader of oncogenic BCR-ABL

Proteolysis targeting chimeras (PROTAC), acting as a degrader of oncogenic BCR-ABL

An impurity formed in Darapladib production

Potent Selective serotonin reuptake inhibitor (SSRI)

Novel inhibitor of L,L-diaminopimelate aminotransferase (DapL)

Potent and selective fluorescent adenosine A1 receptor agonist

Lipid bilayer modulator which likely inserts into lipid bilayers in the headgroup region, alters their structure and phase behavior, thins the bilayer and fluidizes it, allowing even saturated lipid to form fluid bilayers

Novel potent Bax inhibitor, showing concentration-dependent inhibition of liposome permeabilization with improved activity in vitro

Widely used fluorescent detector of nitric oxide in culture medium, tissue sections and biopsy cells

Selective inhibitor of human DPP7

Novel selective and potent DPP7 inhibitor with a DPP7 IC50 value of 480 pM

Novel inhibitor of SET7/9

Novel 5-HT4 receptor agonist to accelerate colonic motor activity in mice

Novel dual extracellular signaling-related kinase (ERK)/PI3K inhibitor

Novel direct AMPK agonist, showing potential anti-cancer activity via inducing apoptosis, cell cycle arrest, suppressing glycolysis and cholesterol synthesis after activation of AMPK in gefitinib-resistant H1975 cells

Novel ERK2 inhibitor

Novel potent and selective agonist of dopamine D 3 receptor (D 3 R; Ki = 5.72 nM)

Novel potent and selective agonist of dopamine D 2 receptor (D 2 R; K i = 4.58 nM)

Novel dopamine D2 receptor antagonist as a potent multi-target ligand of aminergic G protein-coupled receptors (GPCRs) which dose-dependently stimulates growth, survival of neurons, and promotes their integrity

Novel ERK2 inhibitor

Promoter of spinal muscular atrophy (SMA)

Novel antiviral agent, blocking microtubule polymerization, disrupting the Golgi complex and inhibiting viral trafficking to the plasma membrane during virus egress

Novel potent, selective and metabolically stable LRRK2 inhibitor

Highly potent and selective H4R antagonist

Unique first-in-class antibiofilm antibiotic for biofilm-related wound infections caused by Acinetobacter baumannii

Unique first-in-class antibiotic, being more effective at killing pathogenic methicillin resistant Staphylococcus aureus (MRSA) bacteria than two clinical gold-standard antibiotics-vancomycin and gentamicin